Bibliographic information

GuidelineWHO guidelines on leishmaniases: treatment of visceral leishmaniasis and post-kala-azar dermal leishmaniasis in eastern Africa and South-East Asia
Year of Publication2026
Issuing InstitutionWorld Health Organization

Recommendation

New

Visceral leishmaniasis (VL) relapse in South-East Asia. In settings in which primary VL in immunocompetent patients was treated with single-dose liposomal amphotericin B (LAmB) (10 mg/kg by infusion over 2 h), a parasitologically confirmed case of relapse should not be treated with a single dose of LAmB (10 mg/kg by infusion over 2 h).

Recommended in favor

Conditional

Notes and Remarks

⸋ Relapse patients should be diagnosed parasitologically. ⸋ The choice of drugs should include consideration of availability, feasibility and cost. ⸋ Mitefosine should be administered by allometric dosing, particularly for patients weighing<30 kg. Diagnosis of VL relapse requires parasitological confirmation, as serological tests remain positive for several years after cure due to the persistence of antibodies, and the tests cannot reliably distinguish between active and past infection. Polymerase chain reaction (PCR) testing for parasite DNA in blood or bone-marrow aspirates is substantially more sensitive than microscopy, but its use is currently limited to referral hospitals and research centres. In the future, quantitative PCR techniques may be more specific for clinical disease, although proper standardization of PCR techniques and evaluation of their diagnostic accuracy in representative clinical settings are necessary. Until new tests for confirmation of cure are available, diagnosis of relapse cases will require parasitological confirmation.